CARDIFF ONCOLOGY, INC. Proceeds from Issuance or Sale of Equity
CARDIFF ONCOLOGY, INC. (CRDF) reported Proceeds from Issuance or Sale of Equity of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2019-03-06
- CARDIFF ONCOLOGY, INC. proceeds from issuance or sale of equity for the quarter ending 2017-12-31 was -$10.00K.
- CARDIFF ONCOLOGY, INC. proceeds from issuance or sale of equity for the quarter ending 2017-09-30 was $10.00K.
- CARDIFF ONCOLOGY, INC. proceeds from issuance or sale of equity for the quarter ending 2017-06-30 was $100.00K.
- CARDIFF ONCOLOGY, INC. proceeds from issuance or sale of equity for the quarter ending 2017-03-31 was $0.00.
- CARDIFF ONCOLOGY, INC. proceeds from issuance or sale of equity for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. proceeds from issuance or sale of equity for fiscal 2017 was $100.00K.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 4 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 7 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-06 | |||||
| 2017-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $0.00 derived: sum of 2 quarters · filed 2019-03-06 | $100.00K derived: sum of 3 quarters · filed 2019-03-06 | $100.00K 10-K · filed 2019-03-06 | ||
| 2017-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $110.00K derived: sum of 2 quarters · filed 2017-11-09 | $110.00K 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $100.00K 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | |||||
| 2016-12-31 | $2.40M 10-K · filed 2017-03-15 | |||||
| 2016-09-30 | $2.40M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |